Status:
COMPLETED
Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia
Lead Sponsor:
Japan Tobacco Inc.
Conditions:
Type II Hyperlipidaemia
Eligibility:
All Genders
22-65 years
Phase:
PHASE2
Brief Summary
To demonstrate the effect of JTT-705 doses from 300 mg to 900 mg on the elevation of HDL-C and on the inhibition of CETP activity versus placebo, in patients presenting with mild dyslipidaemia. These ...
Eligibility Criteria
Inclusion
- Patients with of Type II hyperlipidaemia
- Patients having lipid values as indicated below:
- HDL-C \< 1.6 mmol/l
- TG \< 4.5 mmol/l
- Male and females between 18 and 65 years old (If female must be post-menopausal, or pre-menopausal and surgically sterile or using an acceptable form of contraception)
Exclusion
- Body Mass Index (BMI) \> 35 kg/m²
- Pregnant, breast feeding, or woman with child bearing potential without an effective method of contraception
- Concomitant use of medications identified in the protocol
Key Trial Info
Start Date :
May 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2001
Estimated Enrollment :
198 Patients enrolled
Trial Details
Trial ID
NCT00686010
Start Date
May 1 2000
End Date
June 1 2001
Last Update
May 29 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Amsterdam, Utrecht, Rotterdam, Nijmegen, Arnhem, Groningen, Dordrecht, Hoorn, Groningen
Amsterdam, Netherlands